Nantkwest Inc (NASDAQ:NK) CEO Patrick Soon-Shiong purchased 3,710,000 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The shares were bought at an average price of $12.12 per share, for a total transaction of $44,965,200.00. Following the acquisition, the chief executive officer now directly owns 23,750,750 shares in the company, valued at approximately $287,859,090. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Nantkwest stock opened at $10.82 on Wednesday. Nantkwest Inc has a one year low of $1.01 and a one year high of $13.11. The stock has a market cap of $980.16 million, a PE ratio of -15.91 and a beta of 3.05. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.10 and a current ratio of 3.10. The stock has a 50-day moving average of $7.03 and a two-hundred day moving average of $5.04.
Nantkwest (NASDAQ:NK) last issued its quarterly earnings data on Monday, May 11th. The biotechnology company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.02). The business had revenue of $0.02 million during the quarter. Nantkwest had a negative net margin of 112,350.85% and a negative return on equity of 51.94%. As a group, sell-side analysts predict that Nantkwest Inc will post -0.54 EPS for the current fiscal year.
Several analysts recently weighed in on the company. BidaskClub upgraded Nantkwest from a “buy” rating to a “strong-buy” rating in a report on Thursday, June 25th. ValuEngine raised Nantkwest from a “sell” rating to a “hold” rating in a research report on Tuesday, March 3rd. Finally, Zacks Investment Research downgraded Nantkwest from a “hold” rating to a “sell” rating in a research report on Tuesday.
A number of large investors have recently bought and sold shares of NK. Credit Suisse AG acquired a new position in Nantkwest during the 4th quarter worth $480,000. Morgan Stanley boosted its position in shares of Nantkwest by 548.4% in the 1st quarter. Morgan Stanley now owns 65,535 shares of the biotechnology company’s stock valued at $189,000 after purchasing an additional 55,428 shares during the period. Renaissance Technologies LLC boosted its position in shares of Nantkwest by 2.5% in the 4th quarter. Renaissance Technologies LLC now owns 1,634,925 shares of the biotechnology company’s stock valued at $6,196,000 after purchasing an additional 39,200 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Nantkwest by 29.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 164,703 shares of the biotechnology company’s stock valued at $625,000 after purchasing an additional 37,660 shares during the period. Finally, Two Sigma Investments LP purchased a new stake in Nantkwest during the 1st quarter valued at approximately $105,000. Institutional investors own 6.19% of the company’s stock.
NantKwest, Inc, a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells.
See Also: Technical Analysis
Receive News & Ratings for Nantkwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest and related companies with MarketBeat.com's FREE daily email newsletter.